BUZZ-Australia's <a href="https://laohu8.com/S/NEU.AU">Neuren Pharmaceuticals</a> drops as US partner seeks EMA re-examination** Shares of Neuren Pharmaceuticals NEU.AX fall 8% to A$12.67, on track for their weakest session since February 5
** The biopharma firm says its partner, Acadia Pharmaceuticals ACAD.O, confirms plan to request re-examination of opinion adopted by Committee for Medicinal Products for Human Use of the European Medicines Agency $(EMA)$
** Re-examination regarding the marketing of trofinetide for the treatment of Rett syndrome in patients two years and older - co
** Australian healthcare stocks .AXHJ down 1.5%, in line with broader benchmark .AXJO which is down 1.2%
** YTD, stock down 31.9%, including the day's move
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.